

**Cholesterol recognition motifs in the transmembrane domain of the tyrosine kinase  
receptor family: the case for TRKB**

Cecilia Cannarozzo, Senem Merve Fred, Caroline Biojone, Plinio C Casarotto\*, Eero Castren

Neuroscience Center - HILife, University of Helsinki, Finland

\* correspondence:

Plinio Cabrera Casarotto, PhD

[plinio.casarotto@helsinki.fi](mailto:plinio.casarotto@helsinki.fi)

Neuroscience Center

Haartmaninkatu 8, B233b

PO Box 63

University of Helsinki, Finland

## ABSTRACT

Cholesterol is an essential constituent of cell membranes. Recently, the discovery of cholesterol recognition aminoacid consensus (CRAC) on proteins indicated a putative direct, non-covalent interaction between cholesterol and proteins. In the present study, we evaluated the incidence of CRAC motifs, and its inverted version (CARC), in the transmembrane region (TMR) of tyrosine kinase receptor family (RTK) in *Caenorhabditis elegans* (nematode); *Drosophila melanogaster* (fruit fly); *Danio rerio* (zebrafish); *Mus musculus* (mouse), and *Homo sapiens* (human) by using *in silico* methods. We found CRAC motifs across all species analyzed, whereas, CARC motifs, comprising the extracellular side of the TMR, were only found in vertebrates.

On top of its contribution to structural properties of cells, cholesterol (or its' metabolites) regulates a myriad of cellular functions culminating in increased neuronal plasticity in the central nervous system. The tropomyosin-related kinase B (TRKB), a member of RTK family, is also a core participant in neuronal plasticity process. Therefore, focusing on TRKB receptor, we observed high homology in TRKB.TMR and conservation of CARC motifs across multiple organisms. Upon the recognition of conserved CARC motif in the TRKB, we compared the effect of point mutations in CARC on structural changes in the TMR of human TRKB. The alignment of wild-type and mutant TMR indicates small changes across the 5 mutations analyzed (Y434F, Y434C, Y434A, V439K and R428A), indicated by the root-mean-squared deviation (RMSD) values for the superimposed structures, average=2.448Å. The TMR point mutation also impacted the physicochemical properties of the models, measured by solvent accessibility. The mutation of the Y, V or R residues in the CARC motif increased the solvent access in the juxtamembrane portions of the TMR, ranging from 150-500%.

In conclusion, it is plausible to consider a potential role for CARC/CRAC motifs in the function of RTK family TMR. The presently described CARC motif in TRKB.TMR may exert its effect by regulating the receptor capability to interact with the polar heads of membrane phospholipids.

**Keywords:** cholesterol-recognition motif, TRKB, tyrosine kinase receptor, BDNF

## INTRODUCTION

The human brain contains 23% of the body's total cholesterol, mostly in the myelin sheath of oligodendrocytes [1,2]. The blood brain barrier prevents lipoprotein or cholesterol transport to the brain, therefore local *de novo* synthesis takes place. In mouse brain, cholesterol synthesis peaks during the second postnatal week and then decreases significantly, without being influenced by sex or blood cholesterol concentration [3,4]. During early development, neurons produce cholesterol autonomously [4–6]. In later stages, cholesterol is synthesized by glial cells. However, it is not defined whether it is a constant or regulated production [4,7].

Cholesterol, which can be localized on both leaflets of the plasma membrane [8], induces changes in the membrane physical properties such as fluidity [9] and curvature [10] or interacts with transmembrane domain to regulate protein function [11,12]. Cholesterol is a core constituent of micro-domains known as lipid rafts, which serve as signaling platforms for several pathways [13–15]. In the nervous system, cholesterol interaction with membrane proteins influences several crucial events such as exocytosis of synaptic vesicles [16], synaptic activity, connectivity, plasticity, signal transduction, transmission, and cell survival [17–19]. The neurotrophic receptor subfamily is one of the most prominent representatives of tyrosine kinase receptor family (RTK), given its crucial role in regulating neural plasticity [20]. The tropomyosin-related kinase receptors (TRK) comprise three members TRKA, TRKB and TRKC, which are phosphorylated in different tyrosine residues in the intracellular portion upon activation by their high-affinity ligands: NGF, BDNF and NT-3, respectively [21]. TRKA and TRKC (NTRK1 and NTRK3, respectively) are located in lipid rafts, while TRKB (NTRK2) presence in rafts occurs upon BDNF stimulation [22,23]. Functionally, in the absence of ligand, TRKA and TRKC, but not TRKB, induce cell death through a p75NTR-mediated mechanism [20].

*In silico* models suggest that two cholesterol molecules can interact in a tail-to-tail fashion as transbilayer dimer [24,25] or back-to-back through their flat alpha faces, leaving the beta sides accessible for interactions with proteins [26]. On these target proteins, two consensus motifs with predictive value have been defined [27]: the Cholesterol Recognition Aminoacid Consensus sequence (CRAC) and its 'inverted' version - CARC [28,29]. The CRAC linear sequence, from N- to C-terminus, comprises an apolar residue [leucine (L) or valine (V)], one to five amino acids of any kind, an aromatic amino acid [tyrosine (Y) or phenylalanine (F)], one to five amino acids of any kind, and a basic residue [arginine (R) or lysine (K)] [11]. CARC consists of the same algorithmic pattern in the opposite direction, with tryptophan (W) as alternative aromatic residue, with higher affinity for cholesterol than CRAC [11,27]. Several proteins have been identified to contain CRAC/CARC motifs, such as nicotinic acetylcholine (nAChR), type-3 somatostatin, and GABA-A receptors [11,30,31].

Thus, the aim of the present study was to evaluate the incidence of cholesterol interacting motifs (CRAC and CARC) in the RTK family. Given the promiscuous nature of CRAC motifs, we focused on the RTK TMR, where such interaction has a higher probability of occurrence. Transmembrane domains are crucial for proper positioning in the lipid bilayer of biological membranes [11]. Interaction of transmembrane domains of embedded integral proteins with the lipid component of the bilayer provides a diffusion barrier, and contains environment to maintain electrochemical properties [32]. Upon the recognition of CARC in TRKB, we determined the impact of a series of mutations in the transmembrane region physicochemical properties, measured as solvent accessibility to the aminoacid residues, and conformation in the human TRKB.TMR.

## **METHODS**

### **Data mining**

For data mining, we used 144 hand-curated inputs for RTK family (code 2.7.10.1) from UniProt database [33]. The canonical primary structure of TMR (transmembrane domain and the flanking 5 aminoacid residues, from N- and C-terminal) of RTK from each target of human (52 proteins), mouse (51 proteins), zebrafish (14 proteins), fruit fly (12 proteins), and nematode *C. elegans* (15 proteins) database were extracted. The TMR FASTA sequences for each protein was manually screened for the presence of cholesterol recognition alignment consensus (both CRAC and its inverted version CARC) [8,11]. Next, we searched for putative pathogenic mutations using SwissVar, ClinVar and COSMIC databases [34–36].

### **Homology of TRKB (and TMR) across species**

The homology of TRKB.TMR (and full length sequences) among several species: *D. rerio* (zebrafish), *G. gallus* (chicken), *C. familiaris* (dog), *R. norvegicus* (rat), *M. musculus* (mouse), *P. troglodytes* (chimpanzee), and *H. sapiens* (human), was determined using the align tool in UniProt database [33].

### **Alignment and solvent accessibility of models**

The models of human TRKB.TMR (in this case with extra 10aa residues in each terminal) were generated in the RaptorX server [37], using wild-type (WT) and mutated FASTA sequences. The point mutation Y434F was chosen to exclude only the -OH group, but protect the aromatic ring structure of tyrosine. Y434A mutation was induced to examine the effects of the aromatic ring of tyrosine removal. Finally, Y434C mutation was introduced based on evidence showing the association of this particular change with hyperphagic obesity syndrome, which also causes defective memory, learning, and nociception [38,39]. The V439K mutation was chosen aiming to

change an apolar/neutral to a basic aminoacid residue, and the same reason was considered for the R428A mutation. The models were aligned with WT for comparison, and the root-mean-squared deviation (RMSD) between the backbone carbon structure calculated by the server. The relative solvent accessibility per residues was calculated using PyMOL (v2.0 Schrödinger, LLC), and normalized by WT values.

## RESULTS

### Data mining

The presence of CRAC motifs were found throughout all the species analyzed [human (11 of 52 proteins), mouse (10 of 51 proteins), zebrafish (2 of 14 proteins), fruit fly (2 of 12 proteins), and *C. elegans* (2 of 15 proteins)] (figure 1), however, the presence of CARC motifs in RTK family was observed only in vertebrates, with 3 in human, 3 in mouse and 2 in zebrafish RTK. None of the proteins analyzed was found to carry CRAC and CARC motifs simultaneously. The ClinVar and COSMIC databases indicated five proteins (see table 1) comprising 8 mutations in the CRAC/CARC domains associated with central nervous system, endocrine disorders or cancer. Full list of proteins positive to CRAC/CARC are listed in table 1, the full list of proteins examined from each species can be found in the deposited raw data (DOI:[10.6084/m9.figshare.7935980](https://doi.org/10.6084/m9.figshare.7935980)).

### Homology of TRKB (and TMR) across species

Upon the identification of CARC motif in TRKB (human and mouse: REHLSVYAVVV; zebrafish: RVAVYIVV), the homology between TRKB.TMR sequences of several species (human, chimpanzee, mouse, rat, dog, chicken and zebrafish), listed in table 2, was examined using UniProt [33]. Over 90% of homology was found in both TRKB.TMR and full length TRKB of human, chimpanzee, mouse, rat and dog. The homology results of paired comparison between the species analyzed are organized in figure 2, where green gradient highlights the percentage of similarity between the sequences. For comparative purposes, we also determined the homology of the full length TRKB among those species. The homology results of paired comparisons are also organized in figure 2, with red gradient highlighting the percentage similarity between sequences.

### Alignment and solvent accessibility of models

We proceeded with human TRKB.TMR to analyze the solvent accessibility following point mutations on tyrosine, valine or arginine in this region. Based on the assessment of solvent accessibility, we detected a prominent increase in the exposed surface to water (ranging from 150-500%) at the two juxtamembrane regions (figure 3a-e). On the other hand, the point mutations induced small morphological changes when the wild-type and mutant models were aligned, as

indicated by the RMSD values (figure 3f-j). The relative solvent accessibility used in the present study is an indication of the surface exposure of the aminoacid residues in a polypeptide sequence [40]. Although simple, this parameter indicates putative conformational alterations in proteins that may translate into functional changes. Thus, even mild/neutral mutations such as Y to F in the CARC motif alters the physicochemical properties of the TMR.

## DISCUSSION

In the present study, we evaluated the incidence of cholesterol-recognition motifs in the receptor tyrosine-kinase family (RTK) from mouse, human, zebrafish, fruit fly, and nematode *C. elegans*. We found that while the *bona fide* CRAC, located in the C-terminal portion of transmembrane domain [11], is found in all the species analyzed, its inverted version - CARC - was only observed in vertebrates. Furthermore, we found that TRKB, a tyrosine-kinase receptor crucial for neuronal plasticity, contains a CARC sequence in the TMR. This motif is conserved across different species, and point mutations of the tyrosine, valine or arginine residues alter the solvent accessibility of the juxtamembrane regions of TRKB.

Cholesterol can interact with membrane proteins in several ways, one of its most prominent effect involves a direct post-translational modification on members of the Hedgehog pathway; particularly described in *Drosophila sp.* [41,42]. In this model organism, cholesterol is also found to regulate membrane depolarization through transient receptor potential (TRP) channels [43], and serves as a precursor for ecdysteroids, which in turn regulate several steps of the fly development [44]. In nematodes, such as *C. elegans*, cholesterol is only obtained from diet, although these worms can modify the basic steroid structure into derivatives [45]. In both organisms, cholesterol appears to play a major role as signaling molecule with post translational modifications of proteins as the main mechanism [46].

Although neurons synthesize the absolute minimum necessary cholesterol, glial production and release of lipoproteins supply neuronal demand during development and in adulthood [47]. In particular, apolipoprotein E (APOE) is synthesized primarily by astrocytes and glial cells [4,48]. Glia-derived cholesterol stimulates synapse formation and synaptic efficacy [49,50]. In the presynaptic plasma membrane, the cholesterol-rich lipid rafts are necessary for SNARE-dependent exocytosis of vesicles with high content of cholesterol. At the postsynaptic level, such rafts organize the disposition of receptors, protein scaffold and signaling cascades [49,50]. Importantly, cholesterol removal from neuronal cultures impairs exocytosis of synaptic vesicles [16], synaptic transmission [18] and neuronal viability [19]. In addition, it induces clustering of AMPA receptors, and hinders NMDA-induced long-term potentiation (LTP) in the hippocampus [51,52].

Since it is difficult to directly visualize cholesterol binding motifs and crystallize the

transmembrane domains containing such sequences, two consensus motifs with predictive value have been defined through *in silico* methods [27]: CRAC and its 'inverted' version - CARC [28,29]. The non-covalent binding of cholesterol to specific motifs in proteins has been the focus of various recent studies. For example, cholesterol modulates docking of NMDA receptors into lipid rafts [53], and the function of vanilloid receptors (TRPV1, a member of the TRP family) [54], thus interfering in synaptic plasticity. Increased cholesterol concentration enhances the plasticity and the flexibility of 5HT1a dimers and adrenergic receptors [55,56]. Given the opposed dispositions of CARC and CRAC motifs, it is possible to assume the co-existence of both in the same transmembrane domain, and their potential interaction with two cholesterol molecules in a tail-to-tail configuration [27]. However, none of the analyzed TMR of RTK family members in the present study displayed co-existing CARC and CRAC motifs.

Interestingly, we only observed the occurrence of CARC motifs on zebrafish, mouse and human RTK family, and TRKB.TMR is highly conserved among vertebrates, similarly to full length TRKB. However, the TRKB.TMR CARC sequence from chicken differs in the juxtamembrane residue from the other species compared (see table 2). It is plausible to consider two optional scenarios, the role of R/K (charged, basic residues) is fulfilled by glutamate (E), which is also charged at pH 7, although negatively; or by glutamine (N), which is not charged but carries a basic amino group. Additionally, for the second possibility it is also necessary to relax the proposed '5-residue rule' between the Y and the juxtamembrane residue [57], since N is located 6 residues apart from the central Y.

As mentioned above, TRKB plays a crucial role in several aspects of neural plasticity. The activation of this receptor is associated with the reopening of visual critical period [58], and the formation, retention and recall of memory [59,60]. Increased activity of TRKB is linked to the occurrence of epilepsy, while blockade of such signaling normalizes the condition [61,62]. Whole genome sequencing performed on patients with developmental and epileptic encephalopathy (DEE) links a *de novo* missense variant of TRKB (*NTRK2*) to the disease pathology [38]. Patients carrying cysteine at residue 434 instead of tyrosine, located inside TRKB CARC motif, were observed to have a similar phenotype varying from severe global developmental delay or intellectual disability to visual and feeding impairments [38]. Therefore, it is possible to speculate that such Y434C mutation, interfering with TRKB-cholesterol interaction, leads to impairment of adequate TRKB activity and function.

Neurotrophins induce homodimerization of TRK monomers to activate downstream kinases [63]. However, through a p75NTR-dependent mechanism, TRKA and TRKC receptors may induce cell death in the absence of their ligands, NGF or NT-3, respectively. On the other hand, TRKB does not act as death-inducing receptor when coupled to p75NTR [64]. In this sense, it is

suggested that TRKA and TRKC interaction with p75NTR is a necessary step for moving the complex to lipid rafts, where the p75NTR-dependent death signal is triggered through its cleavage by gamma secretase [20]. TRKB was not observed to display such co-occurrence with p75-NTR in lipid rafts. The association of TRKA and TRKC with p75NTR in rafts involves the transmembrane domain of these receptors, given that a chimeric TRKB carrying TRKA transmembrane sequence requires BDNF for survival signal [20]. Curiously, p75NTR possesses a classical CRAC domain in its TMR: VVGLVAYIAFKR; conserved in human, mouse, rat and chicken.

TRKB is found in lipid rafts only upon activation by BDNF [22]. Interestingly, when cholesterol is sequestered, TRKB translocation to lipid rafts is impaired, and BDNF-dependent potentiation is prevented [22]. However, loss of cholesterol in hippocampal cultures is associated with increased baseline activity of TRKB [65]. These opposite outcomes might be due to a differential modulation exerted by cholesterol, depending on the challenge to TRKB receptor (basal vs BDNF-stimulated), cell type/origin and stage of differentiation. Another possibility poses that cholesterol affects TRKB activity in a bell-shaped manner, where higher as well as lower concentrations of cholesterol impedes, instead of promoting, TRKB phosphorylation. In fact, the decrease of cholesterol levels by beta-cyclodextrin was found to differentially modulate the neurite growth of hippocampal and cortical cultured neurons. In hippocampal cells, the decrease of cholesterol levels induces an increase in neurite length and number, while no effect was observed in cortical cells. Interestingly, cultures of hippocampal cells show higher levels of cholesterol than the cortical counterparts [66]. Altogether, it is a provocative idea to consider TRKB as a 'sensor' of cholesterol levels in the cell membrane via CARC. Thus, TRKB would trigger the synaptic maturation or neurite growth only if the cholesterol levels are ideal for such changes. This assumption, however, remains to be tested.

Our data indicates increased solvent accessibility to the juxtamembrane regions of mutant TRKB in all the residues analyzed. The changes varied from 150-500% above the levels found in wild-type sequence. The increase in the hydrophilicity of juxtamembrane could implicate a decrease in the BDNF-induced movement of TRKB towards the lipid raft compartments, where the changes in TMR orientation may be altered, due to membrane thickness [67,68].

According to *in silico* analysis of cholesterol interaction with CARC motifs, the Y to F, or Y to W mutations do not interfere with the motif interaction with cholesterol. However, these analyses were performed in multipass or multi-subunits transmembrane receptors, such as nicotinic cholinergic [27] or GPCR receptors [55,56]. Given that TRKB, as well as virtually all members of the RTK family, possess a single transmembrane domain, small changes in this region may impact their function, while not detected in the multipass proteins or to the direct interaction with cholesterol. The exception was found to be Q19238 (Putative tyrosine-protein kinase F09A5.2)




from *C. elegans*, with 2 transmembrane domains, although none is CRAC/CARC-positive.

The insights in the present study could serve as a primary step for experimental testing of the impact of mutations in CRAC/CARC motifs in TMR of RTK family. However, we are limited by only considering the role of CRAC/CARC motifs in the TMR of RTKs. Given the promiscuous properties of these motifs, it is plausible to assume multiple false positive CRAC/CARCs alongside proteins, making the data mining and putative *in silico* or *in vitro* analysis difficult to perform. Therefore, more studies focused on refining the algorithms for detecting these motifs are necessary.

## **Funding**

Funding for this study was provided by ERC (#322742, iPLASTICITY), EU Joint Programme, Neurodegenerative Disease Research (JPND) (#301225, CircProt), Academy of Finland (#294710 and #307416), Jane and Eljas Erkkö Foundation, and Sigrid Juselius Foundation.

## Figures and tables



**Figure 1.** (a) workflow of data mining. The TMR (transmembrane sequence +5aa residues from each N- and C-terminal sides) of curated entries found in UniProt using the code for tyrosine kinase receptor family (2.7.10.1) were blasted against the library of cholesterol recognition and alignment consensus combinations. The incidence of CRAC and CARC motifs in (b) human, (c) mouse, (d) zebrafish, (e) fruit fly and (f) *C. elegans* TMR of RTK family members. (g) library of CRAC and CARC sequences (all the combinations used can be found in the stored data). The yellow highlighted region of the sequences must be embedded into the cell membrane.

**Table 1.** CRAC and CARC(\*)-positive proteins


Unipro ID	Protein name	Mutation in CRAC/CARC
<b><i>H. sapiens</i></b>		
Q9UM73	ALK tyrosine kinase receptor	
Q16620*	BDNF/NT-3 growth factors receptor	Y434C
P29320	Ephrin type-A receptor 3	I564V
P11362	Fibroblast growth factor receptor 1	
P22455	Fibroblast growth factor receptor 4	
P08069	Insulin-like growth factor 1 receptor	
P06213	Insulin receptor	F978Y
P07333	Macrophage colony-stimulating factor 1 receptor	L536V, Y540S, K541T, K543M
P10721	Mast/stem cell growth factor receptor Kit	
O15146	Muscle, skeletal receptor tyrosine-protein kinase	
Q15303	Receptor tyrosine-protein kinase erbB-4	
Q12866	Tyrosine-protein kinase Mer	I518V
Q01974*	Tyrosine-protein kinase receptor ROR2	
P34925*	Tyrosine-protein kinase RYK	
<b><i>M. musculus</i></b>		
P97793	ALK tyrosine kinase receptor	
P15209*	BDNF/NT-3 growth factors receptor	
Q60750	Ephrin type-A receptor 1	
P29319	Ephrin type-A receptor 3	
P16092	Fibroblast growth factor receptor 1	
Q03142	Fibroblast growth factor receptor 4	
P15208	Insulin receptor	
Q60751	Insulin-like growth factor 1 receptor	
P09581	Macrophage colony-stimulating factor 1 receptor	
P05532	Mast/stem cell growth factor receptor Kit	
Q61006	Muscle, skeletal receptor tyrosine-protein kinase	
Q9Z138*	Tyrosine-protein kinase transmembrane receptor ROR2	
Q01887*	Tyrosine-protein kinase RYK	
<b><i>D. rerio</i></b>		
Q9I8N6	Macrophage colony-stimulating factor 1 receptor	
Q8JFR5	Mast/stem cell growth factor receptor kita	
B8JLJ1*	Tyrosine-protein kinase receptor (Ntrk2a)	
A0A0R4ILA2*	Tyrosine-protein kinase receptor (Ntrk2b)	
<b><i>D. melanogaster</i></b>		
P09208	Insulin-like receptor	
P83097	Putative tyrosine-protein kinase Wsck	
<b><i>C. elegans</i></b>		
P34891	Receptor-like tyrosine-protein kinase kin-15	
G5EGK5	Tyrosine-protein kinase receptor cam-1	

UniProt ID	NTRK2	human	chimpanzee	mouse	rat	dog	chicken	zebrafish
Q16620	human		100.00	93.92	93.55	98.30	77.13	60.43
A0A2J8MRP9	chimpanzee	100.00		93.92	93.55	98.30	77.13	60.43
P15209	mouse	91.18	91.18		98.54	93.80	76.49	60.39
Q63604	rat	94.12	94.12	97.06		93.55	76.49	60.15
E2RKA1	dog	97.06	97.06	94.12	91.18		77.49	60.68
Q91987	chicken	41.18	41.18	44.12	44.12	41.18		61.09
A0A0R4ILA2	zebrafish 2b	35.29	35.29	35.29	35.29	35.29	50.00	

**Figure 2.** Percent of homology of full length (red) and TMR (green) of TRKB. The aa sequence of full length and TMR of TRKB (NTRK2) from different species were verified for homology in UniProt database.

**Table 2.** CARC-containing sequences (red) in TRKB.TMR among vertebrate species.

UniProt	Species	TMR sequence
Q16620	<i>H. sapiens</i>	TGREHLSVYAVVVIASVVGFCLLVMLFLLKLARH
A0A2J8MRP9	<i>P. troglodites</i>	TGREHLSVYAVVVIASVVGFCLLVMLFLLKLARH
P15209	<i>M. musculus</i>	SNREHLSVYAVVVIASVVGFCLLVMLLLLKLARH
Q63604	<i>R. norvegicus</i>	TNREHLSVYAVVVIASVVGFCLLVMLLLLKLARH
E2RKA1	<i>C. familiaris</i>	SGREHLSVYAVVVIASVVGFCLLVMLFLLKLARH
Q91987	<i>G. gallus</i>	ENEDSITVYVWVGIAALVCTGLVIMLIILKFGRH
A0A0R4ILA2	<i>D. rerio</i>	PLEDRVAVYIVWGIAGVALTGCILMLVFLKYGRS



**Figure 3.** The aa sequences of human TRKB TMR (wild-type and carrying a point mutation the CARC motif) were submitted to RaptorX server. The solvent accessibility to the modeled TMRs and alignment of mutant models against wild-type TMR with the root mean squared deviation (RMSD, values expressed in Å) between the atoms in the backbone of the chains for (a,f) Y434F, (b,g) Y434C, (c,h) Y434A, (d,i) V439K and (e,j) R428A mutations. Gray boxes indicate the TM domain, dotted vertical line indicates the location of point mutation. Yellow: TMR of wild-type; blue: TMR of mutant; red: site of mutation.

## REFERENCES

1. Dietschy JM, Turley SD. Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. *J Lipid Res.* 2004;45: 1375–1397.
2. Martin MG, Ahmed T, Korovaichuk A, Venero C, Menchón SA, Salas I, et al. Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents. *EMBO Mol Med.* 2014;6: 902–917.
3. Quan G, Xie C, Dietschy JM, Turley SD. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. *Developmental Brain Research.* 2003;146: 87–98.
4. Pfrieger FW, Ungerer N. Cholesterol metabolism in neurons and astrocytes. *Prog Lipid Res.* 2011;50: 357–371.
5. Chaves EIP de, Rusiñol AE, Vance DE, Campenot RB, Vance JE. Role of Lipoproteins in the Delivery of Lipids to Axons during Axonal Regeneration. *J Biol Chem.* 1997;272: 30766–30773.
6. Niewieg K, Schaller H, Pfrieger FW. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. *J Neurochem.* 2009;109: 125–134.
7. Saito K, Dubreuil V, Arai Y, Wilsch-Bräuninger M, Schwudke D, Saher G, et al. Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosis. *Proceedings of the National Academy of Sciences.* 2009;106: 8350–8355.
8. Fantini J, Di Scala C, Evans LS, Williamson PTF, Barrantes FJ. A mirror code for protein-cholesterol interactions in the two leaflets of biological membranes. *Sci Rep.* 2016;6: 21907.
9. Maguire PA, Druse MJ. The influence of cholesterol on synaptic fluidity, dopamine D1 binding and dopamine-stimulated adenylate cyclase. *Brain Res Bull.* 1989;23: 69–74.
10. Lee AG. How lipids affect the activities of integral membrane proteins. *Biochim Biophys Acta.* 2004;1666: 62–87.
11. Fantini J, Barrantes FJ. How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains. *Front Physiol.* 2013;4: 31.
12. Elkins MR, Sergeev IV, Hong M. Determining Cholesterol Binding to Membrane Proteins by Cholesterol <sup>13</sup>C Labeling in Yeast and Dynamic Nuclear Polarization NMR. *J Am Chem Soc.* 2018;140: 15437–15449.
13. Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, et al. SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. *EMBO J.* 2001;20: 2202–2213.
14. Pereira DB, Chao MV. The tyrosine kinase Fyn determines the localization of TrkB receptors in lipid rafts. *J Neurosci.* 2007;27: 4859–4869.
15. Zonta B, Minichiello L. Synaptic membrane rafts: traffic lights for local neurotrophin signaling? *Front Synaptic Neurosci.* 2013;5. doi:10.3389/fnsyn.2013.00009
16. Linetti A, Fratangeli A, Taverna E, Valnegri P, Francolini M, Cappello V, et al. Cholesterol reduction impairs exocytosis of synaptic vesicles. *J Cell Sci.* 2010;123: 595–605.
17. Liu J-P, Tang Y, Zhou S, Toh BH, McLean C, Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. *Mol Cell Neurosci.* 2010;43: 33–42.
18. Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. *Mol Cell Neurosci.* 2005;29: 190–201.
19. Michikawa M, Yanagisawa K. Inhibition of Cholesterol Production but Not of Nonsteroid Isoprenoid Products Induces Neuronal Cell Death. *J Neurochem.* 1999;72: 2278–2285.
20. Dekkers MPJ, Nikolettou V, Barde Y-A. Cell biology in neuroscience: Death of developing neurons: new insights and implications for connectivity. *J Cell Biol.* 2013;203: 385–393.
21. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. *Annu Rev Neurosci.* 2001;24: 677–736.
22. Suzuki S, Numakawa T, Shimazu K, Koshimizu H, Hara T, Hatanaka H, et al. BDNF-induced recruitment of TrkB receptor into neuronal lipid rafts: roles in synaptic modulation. *J Cell Biol.* 2004;167: 1205–1215.
23. Suzuki S, Kiyosue K, Hazama S, Ogura A, Kashihara M, Hara T, et al. Brain-Derived Neurotrophic Factor Regulates Cholesterol Metabolism for Synapse Development. *Journal of Neuroscience.* 2007;27: 6417–6427.
24. Harris JS, Epps DE, Davio SR, Kezdy FJ. Evidence for Transbilayer, Tail-to-Tail Cholesterol Dimers in Dipalmitoylglycerophosphocholine Liposomes. *Biochemistry.* 1995;34: 3851–3857.
25. Rukmini R, Rawat SS, Biswas SC, Chattopadhyay A. Cholesterol Organization in Membranes at Low Concentrations: Effects of

- Curvature Stress and Membrane Thickness. *Biophys J.* 2001;81: 2122–2134.
26. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola V-P, Chien EYT, et al. A Specific Cholesterol Binding Site Is Established by the 2.8 Å Structure of the Human  $\beta$ 2-Adrenergic Receptor. *Structure.* 2008;16: 897–905.
  27. Di Scala C, Baier CJ, Evans LS, Williamson PTF, Fantini J, Barrantes FJ. Chapter One - Relevance of CARC and CRAC Cholesterol-Recognition Motifs in the Nicotinic Acetylcholine Receptor and Other Membrane-Bound Receptors. In: Levitan I, editor. *Current Topics in Membranes.* Academic Press; 2017. pp. 3–23.
  28. Baier CJ, Fantini J, Barrantes FJ. Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor. *Sci Rep.* 2011;1: 69.
  29. Li H, Papadopoulos V. Peripheral-Type Benzodiazepine Receptor Function in Cholesterol Transport. Identification of a Putative Cholesterol Recognition/Interaction Amino Acid Sequence and Consensus Pattern. *Endocrinology.* 1998;139: 4991–4997.
  30. Jamin N, Neumann J-M, Ostuni MA, Vu TKN, Yao Z-X, Murail S, et al. Characterization of the Cholesterol Recognition Amino Acid Consensus Sequence of the Peripheral-Type Benzodiazepine Receptor. *Mol Endocrinol.* 2005;19: 588–594.
  31. Epand RM. Cholesterol and the interaction of proteins with membrane domains. *Prog Lipid Res.* 2006;45: 279–294.
  32. Hunte C. Specific protein-lipid interactions in membrane proteins. *Biochem Soc Trans.* 2005;33: 938–942.
  33. The UniProt Consortium. UniProt: the universal protein knowledgebase. *Nucleic Acids Res.* 2017;45: D158–D169.
  34. Mottaz A, David FPA, Veuthey A-L, Yip YL. Easy retrieval of single amino-acid polymorphisms and phenotype information using SwissVar. *Bioinformatics.* 2010;26: 851–852.
  35. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res.* 2018;46: D1062–D1067.
  36. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Res.* 2019;47: D941–D947.
  37. Källberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, et al. Template-based protein structure modeling using the RaptorX web server. *Nat Protoc.* 2012;7: 1511–1522.
  38. Hamdan FF, Myers CT, Cossette P, Lemay P, Spiegelman D, Laporte AD, et al. High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. *Am J Hum Genet.* 2017;101: 664–685.
  39. Yeo GSH, Connie Hung C-C, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. *Nat Neurosci.* 2004;7: 1187–1189.
  40. Tien MZ, Meyer AG, Sydykova DK, Spielman SJ, Wilke CO. Maximum allowed solvent accessibilities of residues in proteins. *PLoS One.* 2013;8: e80635.
  41. Jeong J, McMahon AP. Cholesterol modification of Hedgehog family proteins. *J Clin Invest.* 2002;110: 591–596.
  42. Wendler F, Franch-Marro X, Vincent J-P. How does cholesterol affect the way Hedgehog works? *Development.* 2006;133: 3055–3061.
  43. Peters M, Katz B, Lev S, Zaguri R, Gutorov R, Minke B. Depletion of Membrane Cholesterol Suppresses Drosophila Transient Receptor Potential-Like (TRPL) Channel Activity. *Curr Top Membr.* 2017;80: 233–254.
  44. Niwa YS, Niwa R. Neural control of steroid hormone biosynthesis during development in the fruit fly *Drosophila melanogaster*. *Genes Genet Syst.* 2014;89: 27–34.
  45. Kurzchalia TV, Ward S. Why do worms need cholesterol? *Nat Cell Biol.* 2003;5: 684–688.
  46. Mann RK, Beachy PA. Cholesterol modification of proteins. *Biochim Biophys Acta.* 2000;1529: 188–202.
  47. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. *Science.* 2001;294: 1354–1357.
  48. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. *J Clin Invest.* 1985;76: 1501–1513.
  49. Pfrieger FW. Role of cholesterol in synapse formation and function. *Biochimica et Biophysica Acta (BBA) - Biomembranes.* 2003;1610: 271–280.
  50. Pfrieger FW. Outsourcing in the brain: Do neurons depend on cholesterol delivery by astrocytes? *Bioessays.* 2003;25: 72–78.
  51. Frank C, Rufini S, Tancredi V, Forcina R, Grossi D, D'Arcangelo G. Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. *Exp Neurol.* 2008;212: 407–414.
  52. Martín MG, Pfrieger F, Dotti CG. Cholesterol in brain disease: sometimes determinant and frequently implicated. *EMBO Rep.* 2014;15: 1036–1052.
  53. Korinek M, Vyklicky V, Borovska J, Lichnerova K, Kaniakova M, Krausova B, et al. Cholesterol modulates open probability and



- desensitization of NMDA receptors. *J Physiol. Wiley Online Library*; 2015;593: 2279–2293.
54. Jansson ET, Trkulja CL, Ahemaiti A, Millingen M, Jeffries GD, Jardemark K, et al. Effect of cholesterol depletion on the pore dilation of TRPV1. *Mol Pain*. 2013;9: 1.
  55. Prasanna X, Sengupta D, Chattopadhyay A. Cholesterol-dependent Conformational Plasticity in GPCR Dimers. *Sci Rep*. 2016;6: 31858.
  56. Prasanna X, Chattopadhyay A, Sengupta D. Cholesterol Modulates the Dimer Interface of the  $\beta$ 2-Adrenergic Receptor via Cholesterol Occupancy Sites. *Biophys J*. 2014;106: 1290–1300.
  57. Fantini J, Epand RM, Barrantes FJ. Cholesterol-Recognition Motifs in Membrane Proteins. *Adv Exp Med Biol*. 2019;1135: 3–25.
  58. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science*. 2008;320: 385–388.
  59. Karpova NN, Pickenhagen A, Lindholm J, Tiraboschi E, Kuleskaya N, Agústsóttir A, et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. *Science*. 2011;334: 1731–1734.
  60. Bekinschtein P, Cammarota M, Medina JH. BDNF and memory processing. *Neuropharmacology*. 2014;76 Pt C: 677–683.
  61. Heinrich C, Lähtinen S, Suzuki F, Anne-Marie L, Huber S, Häussler U, et al. Increase in BDNF-mediated TrkB signaling promotes epileptogenesis in a mouse model of mesial temporal lobe epilepsy. *Neurobiol Dis*. 2011;42: 35–47.
  62. Liu G, Gu B, He X-P, Joshi RB, Wackerle HD, Rodriguiz RM, et al. Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. *Neuron*. 2013;79: 31–38.
  63. Bothwell M. NGF, BDNF, NT3, and NT4. *Handb Exp Pharmacol*. 2014;220: 3–15.
  64. Nikolettópoulou V, Lickert H, Frade JM, Rencurel C, Giallonardo P, Zhang L, et al. Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. *Nature*. 2010;467: 59–63.
  65. Martin MG, Perga S, Trovò L, Rasola A, Holm P, Rantamäki T, et al. Cholesterol Loss Enhances TrkB Signaling in Hippocampal Neurons Aging in Vitro. *Mol Biol Cell*. 2008;19: 2101–2112.
  66. Ko M, Zou K, Minagawa H, Yu W, Gong J-S, Yanagisawa K, et al. Cholesterol-mediated neurite outgrowth is differently regulated between cortical and hippocampal neurons. *J Biol Chem*. 2005;280: 42759–42765.
  67. McIntosh TJ. X-Ray Diffraction to Determine the Thickness of Raft and Nonraft Bilayers. In: McIntosh TJ, editor. *Lipid Rafts*. Totowa, NJ: Humana Press; 2007. pp. 221–230.
  68. Niemelä PS, Ollila S, Hyvönen MT, Karttunen M, Vattulainen I. Assessing the nature of lipid raft membranes. *PLoS Comput Biol*. 2007;3: e34.